Home pageWXXWY • OTCMKTS
add
Wuxi Biologics Cayman ADR
Chiusura precedente
4,14Â $
Intervallo giornaliero
4,07Â $ - 4,25Â $
Intervallo annuale
2,58Â $ - 13,25Â $
Cap di mercato
70,05Â Mrd HKD
Volume medio
123.749,00
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(CNY) | giu 2024info | Variazione Y/Y |
---|---|---|
Entrate | 4,29Â Mrd | 0,97% |
Spese di gestione | 765,14Â Mln | 21,62% |
Utile netto | 749,54Â Mln | -33,86% |
Margine di profitto netto | 17,48 | -34,51% |
Utili per azione | — | — |
EBITDA | 1,24Â Mrd | -13,32% |
Aliquota fiscale effettiva | 11,36% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(CNY) | giu 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 9,53Â Mrd | 9,60% |
Totale attivo | 56,11Â Mrd | 7,60% |
Totale passivo | 11,46Â Mrd | -12,46% |
Patrimonio netto totale | 44,64 Mrd | — |
Azioni in circolazione | 4,15 Mrd | — |
Prezzo/valore contabile | 0,42 | — |
Redditività dell'attivo | 4,05% | — |
Rendimento sul capitale | 4,62% | — |
Flusso di cassa
Flusso di cassa netto
(CNY) | giu 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 749,54Â Mln | -33,86% |
Liquidità di esercizio | 651,06 Mln | -52,65% |
Contanti da investimenti | -191,26Â Mln | 75,93% |
Contanti da finanziamenti | -737,79Â Mln | -684,70% |
Flusso di cassa netto | -258,16Â Mln | -153,79% |
Flusso di cassa libero | 350,65Â Mln | 52,56% |
Informazioni
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Fondazione
2010
Sito web
Dipendenti
12.435